JAK/MAP kinase pathway activation and TP53 mutations in acute leukemia with megakaryocytic and erythroid differentiation.
JAK/MAP kinase pathway activation and TP53 mutations in acute leukemia with megakaryocytic and erythroid differentiation.
复制标题
巨核细胞和红细胞分化的急性白血病中 JAK/MAP 激酶途径激活和 TP53 突变。
DOI：
10.1038/s41375-018-0145-6
复制
发表时间：
2018
期刊：
影响因子：
11.4
通讯作者：
Park,DavidC
中科院分区：
文献类型：
--
作者：
Xiao,Wenbin;Rampal,Raajit;Zhang,Yanming;Cimera,Robert;Jungbluth,AchimA;Arcila,Maria;Roshal,Mikhail;Park,DavidC
伴有巨核细胞和红系分化的急性白血病（ALMED）是急性髓细胞白血病（AML）的一种非常罕见和高度侵袭性的亚型，其中肿瘤性母细胞除了表现出原成红细胞和成巨核细胞的重叠形态学特征外，还表达红系和巨核细胞谱系相关抗原[1-3]。以前的研究，包括我们的，已经令人信服地证明了
Acute leukemia with megakaryocytic and erythroid differentiation (ALMED) is an exceptionally rare and highly aggressive subtype of acute myeloid leukemia (AML), where the neoplastic blasts express both erythroid and megakaryocytic lineage-associated antigens in addition to exhibiting overlapping morphologic characteristics of proerythroblasts and megakaryoblasts [1–3]. Previous studies, including ours, have convincingly demonstrated